ZNF582 is a zinc finger transcription factor with DNA-binding activity and RNA polymerase II-specific transcriptional regulatory function. While the UniProt annotation describes its involvement in transcriptional regulation, the published literature predominantly characterizes ZNF582 through its epigenetic regulation and tumor suppressive roles across multiple cancer types. In clear cell renal cell carcinoma, ZNF582 overexpression inhibits tumor growth and metastasis by binding to TJP2 and suppressing ERK2 phosphorylation 1. Similarly, in esophageal cancer, ZNF582 downregulation through promoter hypermethylation promotes malignant progression, and ZNF582 restoration inhibits cell viability and metastasis 2. In cervical cancer, ZNF582 promoter methylation levels inversely correlate with radiotherapy sensitivity, with higher methylation predicting improved radiotherapy response, though ZNF582 overexpression paradoxically promotes cell cycle arrest and radioresistance in vitro 3. Clinically, ZNF582 methylation serves as a biomarker across multiple cancer types: in cervical intraepithelial neoplasia (sensitivity 0.71, specificity 0.81) 4, oral dysplasia/cancer (sensitivity 0.85, specificity 0.87 for mild dysplasia) 5, and oral potentially malignant disorders 6. Combined PAX1/ZNF582 methylation testing improves cervical cancer screening accuracy over HPV DNA testing alone 4. ZNF582 methylation correlates with disease progression and cancer recurrence, making it a promising non-invasive diagnostic and prognostic biomarker.